These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27882107)

  • 21. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Incretin Hormones After Orthotopic Liver Transplantation.
    Gámán G; Sárváry E; Gelley F; Doros A; Görög D; Fehérvári I; Kóbori L; Wágner L; Máthé Z; Nemes B
    Transplant Proc; 2015 Sep; 47(7):2207-9. PubMed ID: 26361681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.
    Ohlsson L; Alsalim W; Carr RD; Tura A; Pacini G; Mari A; Ahrén B
    Diabetes Obes Metab; 2013 Jun; 15(6):531-7. PubMed ID: 23331498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
    Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
    J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between the amplitude of glucose excursion and the oxidative/antioxidative system in subjects with different types of glucose regulation.
    Wang Z; Li L; Zheng F; Jia C; Ruan Y; Li H
    Biomed Environ Sci; 2011 Feb; 24(1):68-73. PubMed ID: 21440842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2008 Feb; 63(2):105-9. PubMed ID: 18372550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients.
    Yabe D; Kuroe A; Watanabe K; Iwasaki M; Hamasaki A; Hamamoto Y; Harada N; Yamane S; Lee S; Murotani K; Deacon CF; Holst JJ; Hirano T; Inagaki N; Kurose T; Seino Y
    J Diabetes Complications; 2015 Apr; 29(3):413-21. PubMed ID: 25613093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.
    Ueno H; Tsuchimochi W; Wang HW; Yamashita E; Tsubouchi C; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2015 Jun; 6(2):187-96. PubMed ID: 26055217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes.
    Yuan G; Jia J; Zhang C; Yu S; Dong S; Ye J; Zhu T; Tang B; Qian W; Wang D; Yang L; Zhou L; Mao C
    Endocr J; 2014; 61(5):513-21. PubMed ID: 24621778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
    Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
    J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.